rheumatology
Rare diseases

Australian company has biosimilars in pipeline for arthritic conditions

Australian based biosimilar manufacturer NeuClone has started phase 1 trials of its version of ustekinumab and has plans to launch other biosimilars for arthritic conditions. The Sydney-based manufacturer says it has commenced a dosing trial in Australian centres of a ustekinumab biosimilar candidate, NeuLara, in over 200 healthy volunteers. If approved by the TGA, the ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic